Literature DB >> 3916740

Complete androgen blockade for the treatment of prostate cancer.

F Labrie, A Dupont, A Belanger.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3916740

Source DB:  PubMed          Journal:  Important Adv Oncol        ISSN: 0883-5896


× No keyword cloud information.
  26 in total

1.  Complete androgen blockade as primary treatment for advanced metastatic cancer of the prostate.

Authors:  J F Larsen; S Walter; T Krarup
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 2.  DHEA as physiological replacement therapy at menopause.

Authors:  F Labrie
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

3.  Cyproterone acetate monotherapy in advanced prostatic carcinoma.

Authors:  O Kayigil; O Atahan; A Metin
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 4.  Clinical and economic considerations in the treatment of prostate cancer.

Authors:  E Varenhorst; P Carlsson; K Pedersen
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 5.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

6.  Ocular toxicity of Anandron in patients treated for prostatic cancer.

Authors:  C Harnois; M Malenfant; A Dupont; F Labrie
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

7.  Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.

Authors:  F Labrie; A Dupont; A Belanger; R Lachance; M Giguere
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-10

8.  Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  S Li; C Lévesque; C S Geng; X Yan; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

Review 9.  Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer.

Authors:  J T Isaacs; N Kyprianou
Journal:  Urol Res       Date:  1987

Review 10.  Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.

Authors:  R N Brogden; P Chrisp
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.